/

ATOS

Atossa Therapeutics, Inc.Closed

2.56+0.17 +7.17%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 2.49 −2.63%

Open

2.35

Prev close

2.39

Day range

2.302.60

52-week range

1.7016.50

Volume

70.74K1.11×

Mkt cap

25.55M

P/E ttm

—

Fwd P/E

-0.78

EPS ttm

-4.45

Div yield

0.00%

Earnings

—

From 52w high

−84.48%

Price Chart

Yahoo Finance · delayed

ATOSOct 13, 2026O 2.35H 2.60L 2.30C 2.56+0.17 (+7.11%)Vol 70.70K

SMA 502.41
SMA 2004.41

1Y change −83.75% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ATOS Atossa Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +4.49%
1 month: +1.99%
3 months: +13.27%
6 months: −52.15%
Year to date: −71.07%
1 year: −83.75%

Valuation & ownership

Market cap: 25.55M
Enterprise value: −547.00K
P/E (ttm): —
Forward P/E: -0.78
PEG ratio: —
Price / book: 0.95
Price / sales (ttm): —
EV / EBITDA: 0.01
EPS (ttm): -4.45
EPS (forward): -3.30
Beta (5y monthly): 1.27
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 9.98M
Float: 9.94M
Short % of float: 7.90%
Short ratio (days): 13.35
Held by insiders: 1.85%
Held by institutions: 13.61%
Avg volume (3m): 63.63K
50-day average: 2.40
200-day average: 4.44
52-week change: −83.75%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 60.4
vs 50-day SMA: +6.25%
vs 200-day SMA: −41.89%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 7.90%
Realised vol (20d, ann.): 81.9%
From 52-week high: −84.48%
From 52-week low: +50.59%

ANR

Analyst Consensus

3 analysts

Consensus

Strong buy

1.50 on a 1 (strong buy) – 5 (sell) scale

Mean target

19.00

+642.19% implied

Low 10.00Median 22.00High 25.00

Recommendation trend

Now2 / 0 / 0
1m ago2 / 0 / 0

DES

About Atossa Therapeutics, Inc.

Yahoo Finance profile

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

Sector: Healthcare
Industry: Biotechnology
Employees: 16
Headquarters: Seattle, WA, United States
Website: atossatherapeutics.com
Officers: Dr. Steven C. Quay FCAP, M.D., Ph.D. Chairman, CEO & President
Mr. Mark J. Daniel CPA Chief Financial Officer
Ms. Janet Rose Rea MSPH, RAC Senior Vice President of Research & Development
Ms. Delly Behen P.H.R. Senior Vice President of Business Operations

SEAS

Seasonality · ATOS

2012–2026 · monthly returns

Strongest month Jan +29.66%Weakest month Oct −18.36%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-3.4	-48.2	18.7	2.1	-2.6	-63.1	7.3	20.8	-22.0	31.3			−71.1%
2025	-10.6	-8.3	-13.0	34.3	-13.3	6.4	0.0	-8.4	14.5	2.3	-12.4	-24.4	−37.2%
2024	-3.4	15.3	83.7	-16.1	-13.9	-8.5	13.4	1.5	10.9	-9.2	-5.8	-27.7	+6.8%
2023	50.9	-7.5	-2.7	-11.1	45.3	35.5	-12.7	-28.2	-6.3	-9.5	10.4	18.9	+66.0%
2022	-14.4	-10.9	2.5	-19.2	-4.0	12.4	-13.8	-2.1	-9.8	19.3	-24.2	-29.3	−66.9%
2021	132.6	23.1	-22.4	10.4	38.2	96.3	-52.7	27.1	-14.2	-21.2	-11.7	-29.5	+68.4%
2020	-5.7	-18.2	9.9	63.9	9.2	59.7	-0.5	-32.5	-5.1	-38.4	18.1	-46.0	−39.5%
2019	27.5	13.1	139.5	-15.1	-14.4	-0.4	-18.4	-4.3	-1.5	-18.9	-14.5	15.4	+53.9%
2018	207.7	-17.5	-31.8	-18.9	-26.7	-31.5	2.7	-5.3	-18.2	-25.1	-13.0	-10.5	−67.3%
2017	-2.8	5.1	-47.2	-22.4	-23.7	11.1	-32.0	26.5	23.3	-20.8	-21.4	-21.2	−81.6%
2016	-18.8	61.5	-19.0	11.8	-10.5	-17.6	-10.7	-33.9	-15.3	-12.4	10.9	-30.9	−70.6%
2015	-18.2	64.1	-6.3	-21.1	9.9	-27.6	-9.7	-22.5	-2.5	-16.9	-21.9	-36.0	−77.6%
2014	6.5	-10.9	-23.2	-27.2	19.5	14.3	0.0	10.1	-27.0	-19.3	-17.4	58.9	−38.4%
2013	34.4	22.1	36.7	-23.7	-33.2	16.6	-8.7	-3.2	22.2	-68.7	31.3	0.4	−40.5%
2012												-14.5	−14.5%

INSD

Insider Activity · ATOS

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
May 11, 2026	Steinhart Richard IDirector	Stock Award(Grant) at price 0.00 per share.	10K	—
May 11, 2026	Chen Shu-ChihDirector	Stock Award(Grant) at price 0.00 per share.	10K	—
May 11, 2026	Galli Stephen JDirector	Stock Award(Grant) at price 0.00 per share.	10K	—
May 11, 2026	Remmel H LawrenceDirector	Stock Award(Grant) at price 0.00 per share.	10K	—
May 11, 2026	Finn Jonathan F.Director	Stock Award(Grant) at price 0.00 per share.	10K	—
May 11, 2026	Cigler Tessa M.D.Director	Stock Award(Grant) at price 0.00 per share.	10K	—
Mar 26, 2026	Quay Steven CChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	65K	—
Mar 25, 2026	Daniel Mark James CpaChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	63K	—
Jan 19, 2026	Quay Steven CChief Executive Officer	—	325.2K	—
Jan 19, 2026	Quay Steven CChief Executive Officer	—	331.7K	—
May 20, 2025	Quay Steven CChief Executive Officer	Purchase at price 0.88 per share.	11.2K	$9.89K
Mar 25, 2025	Remmel H LawrenceDirector	Purchase at price 0.70 per share.	10K	$7.00K

13F

Investors Holding ATOS

latest 13F filings of 29 followed managers

Investors holding ATOS
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$254.8K	0.00%	132.04K	+21%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

ATOS

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ATOS

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Atossa Therapeutics, Inc.

Seasonality · ATOS

Insider Activity · ATOS

Congress Trades · ATOS

Investors Holding ATOS

Investors Holding ATOS

Congress Trades · ATOS

Insider Activity · ATOS

Seasonality · ATOS

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Atossa Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News